Tag: ACAAI23
Anaphylaxis Guidelines Regarding What to Do After Administering Epinephrine Expected to...
Paradigm shift based on data and cost-effectiveness analyses.
FDA Fast Tracks Alladapt’s ADP101 for the Treatment of Single and...
Fast Track Designation accelerates ADP101's development path for the treatment of food allergies.
Positive Results Reported for Bryn Pharma’s Epinephrine Nasal Spray in Adults...
If approved, NDS1C may offer patients at risk of anaphylaxis a practical alternative to needle-based administration routes.
Clinical Data Supporting neffy® Epinephrine Nasal Spray Presented at Scientific Meeting
Data builds the case for prompt FDA approval.
DBV Announces Promising 2-Year Results from Ongoing Viaskin “Peanut Patch” Toddler...
81.3% of subjects who completed the oral food challenge reached an eliciting dose of ≥1,000 mg after 24 months of treatment.
Alladapt’s Multi-Allergen OIT Candidate Shows Promise in Clinical Study
Company will begin Phase 3 study in 2024.
Study: Specialized Toothpaste May Lower Risk of Reactions in Adults with...
New study shows specially formulated toothpaste successful in peanut immunotherapy for adults.
